Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Anhedonia in Treatment-Resistant Depression
NCT06230757Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in treatment-resistant depression (TRD), sponsored by University of Colorado Denver. Started Jul 2024; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06230757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06230757.